Aquestive Therapeutics Inc (AQST) concluded trading on Wednesday at a closing price of $3.39, with 11.36 million shares of worth about $38.5 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -0.29% during that period and on February 12, 2025 the price saw a gain of about 14.14%. Currently the company’s common shares owned by public are about 91.18M shares, out of which, 77.48M shares are available for trading.
Stock saw a price change of 9.71% in past 5 days and over the past one month there was a price change of 9.00%. Year-to-date (YTD), AQST shares are showing a performance of -4.78% which increased to 23.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.24 but also hit the highest price of $6.23 during that period. The average intraday trading volume for Aquestive Therapeutics Inc shares is 1.45 million. The stock is currently trading 9.87% above its 20-day simple moving average (SMA20), while that difference is down -2.22% for SMA50 and it goes to -11.31% lower than SMA200.
Aquestive Therapeutics Inc (NASDAQ: AQST) currently have 91.18M outstanding shares and institutions hold larger chunk of about 46.70% of that.
The stock has a current market capitalization of $309.09M and its 3Y-monthly beta is at 2.75. It has posted earnings per share of -$0.45 in the same period. It has Quick Ratio of 5.91. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AQST, volatility over the week remained 6.47% while standing at 5.45% over the month.
Stock’s fiscal year EPS is expected to drop by -235.60% while it is estimated to decrease by -31.16% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on December 17, 2024 offering an Overweight rating for the stock and assigned a target price of $17 to it. Coverage by Leerink Partners stated Aquestive Therapeutics Inc (AQST) stock as an Outperform in their note to investors on May 10, 2024, suggesting a price target of $8 for the stock. On April 11, 2024, Piper Sandler Initiated their recommendations, while on March 28, 2024, Raymond James Initiated their ratings for the stock with a price target of $7. Stock get an Outperform rating from RBC Capital Mkts on April 07, 2021.
